| Ticagrelor | Astrazeneca | ||
| 90mg; Tablet, Oral |
Less Than $1000 mn
|
||
|
More Than 5
|
More Than 5
|
||
|
More Than 5
|
More Than 5
|
||
|
Less Than 5
|
None | ||
| Indicated to reduce the rate of thrombotic cardiovascular (CV) events in patients with acute coronary syndrome (ACS) (unstable angina, non–ST-elevation myocardial infarction, or ST-elevation myocardial infarction) | |||
|
Yes
| |||
| Brilinta | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 |
|---|---|---|---|---|---|---|---|
| ***** (*******) | ******** ** ******* (*** **, ****) | ******* | ******* | ******* | ******* | ******* | ******* |
| ***** | ******** ** ******* (*** **, ****) | ******* | ******* | ******* | ******* | ******* | ******* |
| *********** | ******** ** ******* (*** **, ****) | ******* | ******* | ******* | ******* | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** (*******) | *** \ ** | ***** **,**** | ******* | **** | ***** ***-**** *********** |
| ***** | *** \ ** | ***** **,**** | ******* | ******** ************ | ***** ***-**** *********** |
| *********** | *** \ ** | *** *, **** | ******* | ******** ************ | ***** ***-**** *********** |
| Ticagrelor | Astrazeneca | ||
| 60mg; Tablet, Oral |
Less Than $1000 mn
|
||
|
Less Than 5
|
More Than 5
|
||
|
More Than 5
|
More Than 5
|
||
|
Less Than 5
|
None | ||
| Indicated to reduce the rate of thrombotic cardiovascular (CV) events in patients with acute coronary syndrome (ACS) (unstable angina, non–ST-elevation myocardial infarction, or ST-elevation myocardial infarction) | |||
|
Yes
| |||
| Brilinta | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 |
|---|---|---|---|---|---|---|---|
| ***** (*******) | ******** ** ******* (*** **, ****) | ******* | ******* | *** ********* | ******* | *** ********* | *** ********* |
| ***** | ******** ** ******* (*** **, ****) | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******** ** ******* (*** **, ****) | **** *** | **** *** | ******* | **** *** | **** *** | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** (*******) | ** \ ** | ***** **,**** | ******* | **** | ***** ***-**** *********** |
| ***** | *** \ ********* | ***** **,**** | ******* | ******** ************ | ******* *** **** *** *** **** |
| ******* | ** \ ** | ***** **, **** | ******* | ********* ******** | ***** ***-**** *********** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|